Pharma Business Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Business Week


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Business & Finance

Cancer drug developer posts net loss of $0.17 per share

The company reported a net loss of $7,520,000, or $0.22 per share, for the year ended December 31, 2005, compared with a net loss of $4,921,000, or $0.17 per share, for the year ended December 31, 2004. For the quarter ended December 31, 2005, the company reported a net loss of $2,735,000, or $0.08 per share, compared to a net loss of $1,008,000, or $0.03 per share, for the quarter ended December 31, 2004.

At December 31, 2005, the company had a total of approximately $140,643,000 in cash and marketable securities.

...

• View Other Issues of Pharma Business Week
  
• View Other NewsRx Publications